Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Eisai Set on Streamlining Operations to Drive Drug Innovation: COO
September 13, 2024
- IBM, Kobe Biomedical Cluster Join Hands to Expedite Clinical Trials with AI
September 12, 2024
- Oral COVID Drugs Prescribed to 180,000 Patients: August Data
September 12, 2024
- ViiV’s Vocabria-Rekambys Combo Nets 50% Growth: Japan President
September 11, 2024
- Axcelead DDP, Acadia to Join Forces in Drug Discovery
September 11, 2024
- KM Biologics Bags Option to Osivax’s Universal Flu Vaccines
September 11, 2024
- Kissei, Reborna Form Research Tie-Up for Genetic Rare Diseases
September 10, 2024
- Healios, FDA Agree on Pivotal PIII Design for Cell Therapy MultiStem
September 10, 2024
- New Biomarker Analysis Data Out for Daiichi Sankyo’s TROP2 ADC
September 10, 2024
- Takeda Sheds Working Time by 110,000 Hours via Manufacturing DX
September 9, 2024
- Mitsubishi Chemical Denies Media Report on Pharma Divestiture
September 9, 2024
- Vabysmo Filed for Label Expansion into Angioid Streaks in Japan: Chugai
September 9, 2024
- Nippon Shinyaku DMD Med Gets FDA’s Rare Pediatric Disease Tag
September 9, 2024
- Takeda’s Plasma Therapy Ceprotin Now Available in Japan
September 9, 2024
- Japan Ethical Drug Sales Up 9.6% in July: Crecon
September 9, 2024
- Axcelead DDP, Lilly Ink Research Collaboration Pact
September 6, 2024
- JN.1-Targeting Nuvaxovid Approved in Japan: Takeda
September 6, 2024
- Keytruda Nabs Best-Seller Drug Title for 11th Straight Month: Encise
September 6, 2024
- Organon’s OG-8276A for Dysmenorrhea Hits Goal in Japan PIII Study
September 5, 2024
- Daiichi Sankyo Wins Japan Approval for Updated COVID Jab for JN.1
September 5, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…